There is urgent need to identify and validate prodromal biomarkers in PD patients, to perform further studies assessing both overlapping and disease-specific fMRI abnormalities among parkinsonian syndromes, and to continue technical advances to fully realize the potential of fMRI as a tool to monitor the efficacy of chronic therapies.
Joshua Kahan, Maren Urner, Rosalyn Moran, Guillaume Flandin, André C. Marreiros, Laura Mancini, Mark White, John S. Thornton, Tarek Yousry, Ludvic Zrinzo, Marwan Hariz, Patricia Limousin, Karl Friston, Thomas Foltynie
Discussion(0)
No comments yet. Be the first to comment.